This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Sucroferric oxyhydroxide contains the active component Sucroferric oxyhydroxide. It is classified as a phosphate binder. Sucroferric oxyhydroxide was approved by the U.S. Food and Drug Administration (FDA) on September 5, 2014, to control serum phosphorus levels in patients with chronic kidney disease who are on dialysis.
Mechanism of Action of undefined
Sucroferric oxyhydroxide is a medication that effectively lowers elevated phosphate levels in the blood, primarily in patients with chronic kidney disease (CKD) who are on dialysis. By binding to dietary phosphate in the gastrointestinal tract, this medication prevents its absorption into the bloodstream, thereby reducing the overall phosphate burden. This helps to manage hyperphosphatemia, a common complication of CKD, and minimize associated risks such as bone disease and cardiovascular complications.
Uses of undefined
This medication treats hyperphosphatemia (high phosphate level in blood) in patients with chronic kidney disease (CKD) who are on dialysis.
undefined Drug administaration and Dosage available
To use sucroferric oxyhydroxide, follow the instructions provided by your healthcare professional or the guidelines on the medication packaging. Typically, this medication is taken orally as chewable tablets with meals or shortly after eating. The dosage and frequency of administration will depend on your specific medical condition and individual needs. It is important to chew the tablets thoroughly before swallowing. You may consult your healthcare provider for alternative administration options if you have difficulty chewing.
Warnings, Precautions and Side Effects of undefined
When taking sucroferric oxyhydroxide, it is important to be aware of several warnings. This medication contains iron and may contribute to iron overload. The safety of sucroferric oxyhydroxide during pregnancy, breastfeeding, and in pediatric patients has not been well established. It potentially increases serum calcium levels and the risk of infections.
Close monitoring is necessary for individuals with pre-existing immune, heart, kidney, or liver conditions. Before starting it, it is important to inform your healthcare provider about any medical conditions, medications, or allergies. Additionally, these medications have potential interactions with other drugs. If you experience severe side effects or have concerns, seek medical attention and consult your healthcare provider.
Common side effects of sucroferric oxyhydroxide may include diarrhea, nausea, vomiting, constipation, abdominal pain, and discolored stools. Serious side effects that require immediate medical attention include allergic reactions, severe stomach pain, severe constipation, or black, tarry stools.
Word Of Advice
When taking sucroferric oxyhydroxide, it is important to note that allergic reactions are rare. Still, when it occur, it requires immediate medical attention for symptoms like rash, itching, swelling, difficulty breathing, or dizziness to develop. This medication contains iron and may contribute to iron overload, particularly in at-risk individuals, necessitating regular monitoring of iron levels. Caution should be exercised in individuals with gastrointestinal disorders. The safety during pregnancy, breastfeeding, and in pediatric patients has not been well established. Precautions should be taken to minimize the risk of tooth discoloration by performing good oral hygiene practices. Regular communication with healthcare providers is essential to address concerns and promptly report any concerning symptoms or side effects.
Frequently Asked Question
- Vifor Fresenius Medical Care Renal Pharma France, Electronic medicines compendium (EMC), [Revised on Nov 2020] [ Accessed on 22nd June 2023], https://www.medicines.org.uk/emc/files/pil.3532.pdf
- Fresenius Medical Care North America, US Food and Drug Administration, [Revised on Sept 2014] [ Accessed on 22nd June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205109s001lbl.pdf
The drug information on this page is different from medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.